id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-348244-1py0k53e	Buyse, Marc	Central statistical monitoring of investigator-led clinical trials in oncology	2020-06-23		.txt	text/plain	4053	135	37	A Risk-Based Approach to Monitoring Data-driven risk identification in phase III clinical trials using central statistical monitoring Available at https ://trans celer atebi ophar mainc .com/asset s/rbm-asset s/ (Accessed 14 A statistical approach to central monitoring of data quality in clinical trials Linear mixed-effects models for central statistical monitoring of multicenter clinical trials Use of the betabinomial model for central statistical monitoring of multicenter clinical trials A hercule poirot of clinical research Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional The control of the false discovery rate in multiple testing under dependency Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 vs. UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial Fraud in clinical trials The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials Guidance for industry, investigators, and institutional review boards. The contribution of clinical trials to the overall costs of drug development is not known with precision, but recent estimates suggest that pivotal clinical trials leading to FDA approval have a median cost of US$ 19 million; such costs are even higher in oncology and cardiovascular medicine, as well as in trials with a long-term clinical outcome, such as survival	cache/cord-348244-1py0k53e.txt	txt/cord-348244-1py0k53e.txt
